Oral GLP-1 Therapeutics Market Report Scope and Overview:

The Oral GLP-1 Therapeutics Market was valued at USD 6.81 Billion in 2025 and is projected to reach USD 137.36 Billion by 2035, registering a CAGR of 35.0% from 2026 to 2035.

Oral GLP-1 Therapeutics Market is reinventing the treatment of diabetes and obesity, offering the clinical efficacy of injectable GLP-1 receptor agonists via a painless, once daily oral administration method, making it very easy for patients to start and sustain their treatments. It has been defined by fast growth, triggered by FDA approval of oral semaglutide Wegovy for chronic weight management, fierce competition between the drug makers striving to launch the innovative oral non-peptide candidates, and quick expansion of manufacturing capabilities amid booming global demand. Fast growth is observed in the use of absorption-enhancer peptide, small molecule GLP-1 agonists, and oral peptide delivery systems, taking into account that the pharmaceutical industry, healthcare facilities, and telemedicine continue spending heavily on research of oral drug delivery technologies.

Novo Nordisk A/S received FDA approval for its oral semaglutide Wegovy pill (25 mg) in December 2025, the first oral GLP-1 therapy approved for chronic weight management, with commercial rollout across the United States beginning in early 2026 and expected to reshape the competitive landscape for oral metabolic disease treatment.

Market Size and Forecast

• Market Size in 2026E: USD 9.19 Billion

• Market Size by 2035: USD 137.36 Billion

• CAGR: 35.0% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Oral GLP-1 Therapeutics Market Trends

• Explosive growth continues following FDA approval of oral semaglutide Wegovy for chronic weight management.

• Intense pharmaceutical competition continues as companies race to bring next-generation non-peptide oral candidates to market.

• Rapid manufacturing capacity expansion continues as leading companies invest billions in dedicated oral GLP-1 production facilities.

• Growing telehealth and online pharmacy prescribing continues expanding patient access to oral GLP-1 therapies.

• Rising indication expansion beyond diabetes and obesity continues broadening the addressable oral GLP-1 patient population.

U.S. Oral GLP-1 Therapeutics Market Outlook

The U.S. Oral GLP-1 Therapeutics Market was valued at approximately USD 3.80 Billion in 2025 and is projected to reach approximately USD 70.50 Billion by 2035, registering a CAGR of approximately 34.0% from 2026 to 2035.

Demand across the United States continued to be shaped by the country's position as the first commercial market for both Rybelsus and oral Wegovy, favorable FDA regulatory pathways, and substantial consumer and employer demand for convenient, needle-free metabolic disease treatment. Rising deployment of telehealth-based prescribing platforms by major pharmaceutical companies and digital health providers continued reinforcing the country's position as both the largest and fastest-commercializing oral GLP-1 market. Growing adoption across primary care, endocrinology, and specialty weight-management clinics added further layers of sustained domestic demand well beyond the technology's original diabetes-only use case, with expanding insurance and employer coverage increasingly relying on oral formulations to broaden treatment access.

Eli Lilly and Company reported positive Phase 3 ATTAIN-1 trial results for orforglipron, its investigational once-daily oral, non-peptide GLP-1 receptor agonist, throughout the year, supporting planned global regulatory submissions and positioning the company as Novo Nordisk's primary challenger in the U.S. oral obesity treatment market.

Oral GLP-1 Therapeutics Market Segment Analysis

• By Product, Semaglutide (Rybelsus/Oral Wegovy) segment dominated the Oral GLP-1 Therapeutics Market in 2025 with 78% share; Orforglipron segment is the fastest growing segment.

• By Indication, Type 2 Diabetes Management segment dominated the market in 2025 with 54% share; Obesity & Weight Management segment is the fastest growing segment.

• By Formulation Technology, SNAC-Based Peptide Formulation segment dominated the market in 2025 with 71% share; Non-Peptide Small Molecule Formulation segment is the fastest growing segment.

• By Distribution Channel, Retail Pharmacies segment dominated the market in 2025 with 58% share; Online Pharmacies segment is the fastest growing segment.

By Product: Semaglutide Leads, Orforglipron Emerges as Fastest-Growing Segment

The Semaglutide (Rybelsus/Oral Wegovy) segment was the leader in the Oral GLP-1 Therapeutics Market in 2025 owing to the fact that Novo Nordisk had the first-mover advantage in the launch of Rybelsus for the treatment of type 2 diabetes many years before its competitors, followed by FDA approval for oral Wegovy for chronic weight management in December 2025. The existing physician awareness, the wealth of clinical experience and payer coverage helped semaglutide retain its market leadership in the indications of both diabetes and obesity. The market roll-out of oral Wegovy in 2025 supported semaglutide sales as the biggest contributor to the market value.

The Orforglipron segment is the fastest growing in the Oral GLP-1 Therapeutics Market owing to Eli Lilly's positive Phase 3 ATTAIN-1 results and substantial USD 6.5 billion manufacturing investment positioning the non-peptide candidate for rapid commercial scale-up following anticipated regulatory approval. Growing physician and patient anticipation of a simpler, small-molecule alternative that avoids the dietary restrictions associated with peptide-based oral formulations is driving significant pre-launch interest. Rising competitive investment from Lilly across manufacturing, clinical development, and market access continues positioning orforglipron for exceptionally rapid revenue growth once commercially available.

By Indication: Type 2 Diabetes Dominates, Obesity Gains Fastest Momentum

The Type 2 Diabetes Management segment dominated the Oral GLP-1 Therapeutics Market because Rybelsus was originally approved and commercialized specifically for diabetes years before any oral GLP-1 obesity indication existed. Established reimbursement pathways, extensive endocrinologist and primary care physician familiarity, and years of accumulated real-world clinical evidence sustained diabetes as the default indication driving oral GLP-1 prescribing volume. Continued strong diabetes-indication demand, supported by rising global type 2 diabetes prevalence, contributed to sustained segment dominance throughout the base year even as obesity indications began rapidly expanding.

The Obesity & Weight Management segment is the fastest growing as the December 2025 FDA approval of oral Wegovy opened an enormous new addressable patient population far larger than the diabetes-only market. Rising consumer demand for convenient, needle-free weight-management treatment, combined with expanding employer and insurance coverage for obesity therapeutics, continues driving explosive growth in this indication. Growing direct-to-consumer marketing and telehealth prescribing channels are accelerating patient acquisition at a pace substantially faster than the diabetes segment achieved during its own commercial rollout.

By Formulation Technology: SNAC-Based Peptides Dominate, Small Molecules Grow Fastest

The SNAC-Based Peptide Formulation segment dominated the Oral GLP-1 Therapeutics Market because Novo Nordisk's proprietary absorption-enhancer technology, used in both Rybelsus and oral Wegovy, represents the only commercially approved oral GLP-1 delivery mechanism currently available to patients. Years of clinical validation and manufacturing scale-up experience with SNAC-based coformulation sustained this technology's dominant commercial position. Novo Nordisk's continued investment in expanding SNAC-based manufacturing capacity to meet surging oral Wegovy demand reinforced this formulation approach's leading market position throughout the base year.

The Non-Peptide Small Molecule Formulation segment is the fastest growing due to rising pharmaceutical investment in candidates such as orforglipron, aleniglipron, and CT-996, which avoid the dietary timing restrictions and large pill size associated with peptide-based oral formulations. Growing clinical evidence suggesting comparable efficacy with simpler manufacturing and potentially lower production costs continues attracting substantial competitive investment. Rising anticipation of near-term regulatory approvals for multiple small-molecule candidates is positioning this formulation technology for the fastest growth trajectory across the forecast period.

By Distribution Channel: Retail Pharmacies Dominate, Online Channels Grow Fastest

The Retail Pharmacies segment held the top position within the Oral GLP-1 Therapeutics Market, owing to the availability of an already-existing network of prescription-dispensing infrastructure and geographical accessibility of such pharmacies, as well as the presence of familiarity with the dispensation process among pharmacists of oral medications for diabetes management and weight management among consumers. Retail pharmacy chain organizations remain the predominant dispenser for prescriptions made from traditional primary care and endocrinology practices during the base year.

The Online Pharmacies segment is expected to witness the fastest growth in the Oral GLP-1 Therapeutics Market as telehealth platforms and direct-to-consumer digital health providers increasingly connect patients with prescribers and mail-order fulfillment for weight-management therapies. Growing numbers of patients seeking convenient, discreet access to oral GLP-1 treatment increasingly rely on online platforms offering integrated prescribing, counseling, and home delivery services. Expanding telehealth prescribing regulations continue attracting a broadening base of cost-conscious and convenience-seeking patients toward digital-first treatment access.

Regional Analysis

North America Oral GLP-1 Therapeutics Market Insights

North America led the Oral GLP-1 Therapeutics Market with the largest share of 62.0% in 2025. The region's position as the first commercial market for both Rybelsus and oral Wegovy, favorable FDA regulatory pathways, and substantial consumer and employer demand for convenient, needle-free metabolic disease treatment continued reinforcing this dominant regional position. A deep concentration of leading pharmaceutical manufacturers, telehealth platforms, and specialty weight-management clinics headquartered across the continent gave regional patients early access to next-generation oral GLP-1 therapies well ahead of most other regions.

The United States accounted for roughly 90.00% of regional revenue, anchored by rapid commercial rollout of oral Wegovy, expanding telehealth-based prescribing platforms, and substantial employer and insurance coverage for obesity therapeutics. Canada added further regional demand through its own growing diabetes and obesity treatment infrastructure and expanding public health system interest in oral metabolic disease therapies, and that combined strength kept the continent the largest addressable market for oral GLP-1 developers through the forecast period.

Europe Oral GLP-1 Therapeutics Market Insights

Europe held a meaningful share of global revenue, supported by rising prevalence of type 2 diabetes and obesity, expanding national reimbursement discussions for oral metabolic disease therapies, and continued growth of specialty diabetes and weight-management programs across the region's major economies. Regulatory harmonization under the European Medicines Agency and continued expansion of endocrinology treatment infrastructure continued lowering historically significant barriers to advanced oral GLP-1 technology adoption across the continent.

Germany led demand at roughly 21.50% of European revenue, supported by its substantial pharmaceutical market infrastructure and high per-capita diabetes and obesity treatment volumes among the region's largest economies. The UK and France contributed substantial additional demand through their own expanding metabolic disease treatment programs, and continued European regulatory and reimbursement progress should keep regional demand for oral GLP-1 therapeutics climbing through the forecast period.

Asia Pacific Oral GLP-1 Therapeutics Market Insights

Asia Pacific is advancing at the fastest pace among all regions tracked in this report, growing at a CAGR of approximately 42.0% from 2026 to 2035, driven by rapidly rising diabetes and obesity prevalence, expanding domestic pharmaceutical manufacturing capacity, and growing government-backed investment in metabolic disease treatment access across the region's largest economies. That combination of rising patient populations and expanding domestic GLP-1 development capacity kept the region's growth trajectory well ahead of every other region tracked in this report.

China led the pack, supported by a rapidly growing domestic GLP-1 pipeline from companies such as Innovent Biologics, Gan & Lee Pharmaceuticals, and Sciwind Biosciences, alongside expanding manufacturing capacity. Japan and South Korea contributed meaningful additional demand, with Hanmi Pharmaceutical's regional pipeline and Japan's advanced diabetes treatment infrastructure both reinforcing the region's position as the fastest-growing market tracked in this report.

MEA and Latin America Oral GLP-1 Therapeutics Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by rising diabetes and obesity prevalence, growing government focus on metabolic disease treatment access, and expanding pharmaceutical distribution infrastructure across both areas. As these markets continued building out modern diabetes and obesity care infrastructure, oral GLP-1 therapeutics proved a genuinely efficient way to expand treatment access without the cold-chain and injection-training infrastructure that injectable therapies require.

In the Middle East & Africa region, Saudi Arabia was leading the region in terms of demand due to significant investment that was being made in the healthcare industry by the country. Further demand was being added by UAE due to its burgeoning private healthcare network, along with specialized weight management clinics. In the Latin American market, Brazil was the largest market share-wise in the region due to adoption of diabetes treatments and pharmaceutical distribution.

Market Dynamics

Growth Drivers: Rising Diabetes and Obesity Prevalence and Needle-Free Treatment Preference

The industry is driven by rising global prevalence of type 2 diabetes and obesity, strong patient and physician preference for needle-free treatment over injectable therapy, the landmark FDA approval of oral Wegovy for chronic weight management, and intense pharmaceutical competition to bring next-generation oral candidates to market. As awareness of the treatment-access barriers posed by injectable therapy continues rising, the need for effective, convenient, pill-based metabolic disease treatment continues driving adoption of oral GLP-1 therapeutics.

Rising manufacturing capacity investment across leading pharmaceutical companies continues reinforcing this driver, as companies commit billions of dollars to dedicated oral GLP-1 production facilities to meet surging global demand that current capacity cannot satisfy. Growing telehealth and digital health prescribing infrastructure continues expanding patient access beyond traditional in-person clinical visits, and that combination of manufacturing scale-up and improved access is exactly what keeps demand climbing at such an extraordinary, sustained pace.

Restraints: High Treatment Costs and Manufacturing Capacity Constraints

The substantial cost of oral GLP-1 therapies continues posing a genuine restraint on faster market-wide expansion, particularly across emerging healthcare systems and cost-constrained insurance programs without the reimbursement infrastructure needed to support broad patient access to premium metabolic disease treatment. That cost profile has kept large-scale oral GLP-1 treatment access concentrated among a comparatively small number of well-resourced healthcare systems and self-paying patient populations.

Persistent manufacturing capacity constraints across the industry continue posing a further restraint, as demand for oral GLP-1 therapies has consistently outpaced even the substantially expanded production capacity that leading pharmaceutical companies have brought online. That supply-demand imbalance keeps some patients facing treatment delays or shortages rather than gaining immediate access to oral GLP-1 therapy despite growing physician willingness to prescribe these treatments.

Opportunities: Non-Peptide Small Molecule Expansion and Emerging Market Access

Rising investment in non-peptide small-molecule oral GLP-1 candidates represents a genuinely significant opportunity, as pharmaceutical companies increasingly seek simpler manufacturing processes and formulations that avoid the dietary timing restrictions associated with peptide-based oral therapies. Vendors positioned early in small-molecule candidate development stand to capture meaningful share as this technology continues expanding from clinical-stage pipelines into mainstream commercial availability over the coming years.

Closing treatment-access gaps across emerging pharmaceutical markets offers a second substantial opportunity, as government initiatives aimed at addressing rising diabetes and obesity rates continue creating fresh demand for accessible, cost-effective oral metabolic disease therapies. Companies with proven, scalable oral formulation and manufacturing platforms stand to capture meaningful share as developing economies increasingly view oral GLP-1 access as a genuinely practical way to address a rapidly growing chronic disease burden without injectable therapy's infrastructure requirements.

Recent Developments:

• 2025: Novo Nordisk A/S received FDA approval for its oral semaglutide Wegovy pill (25 mg), the first oral GLP-1 therapy approved for chronic weight management, with commercial rollout beginning in early 2026.

• 2026: Eli Lilly and Company reported positive Phase 3 ATTAIN-1 trial results for orforglipron, its investigational once-daily oral, non-peptide GLP-1 receptor agonist, supporting planned global regulatory submissions for obesity treatment.

• 2025: Eli Lilly and Company announced a USD 6.5 billion investment to build a new manufacturing facility in Houston, Texas, dedicated to producing orforglipron, its experimental oral GLP-1 pill.

• 2026: Structure Therapeutics Inc. reported positive Phase II results for its oral GLP-1 agonist aleniglipron, achieving substantial weight loss and advancing the candidate toward Phase III development.

• 2025: Pfizer Inc. discontinued development of danuglipron, its oral glucagon-like peptide-1 receptor agonist that was being investigated for chronic weight management.

Oral GLP-1 Therapeutics Market key players are:

• Novo Nordisk A/S

• Eli Lilly and Company

• Roche Holding AG

• Structure Therapeutics Inc.

• Viking Therapeutics, Inc.

• Zealand Pharma A/S

• Boehringer Ingelheim International GmbH

• AstraZeneca plc

• Sanofi S.A.

• Sciwind Biosciences Co., Ltd.

• Gan & Lee Pharmaceuticals

• Hanmi Pharmaceutical Co., Ltd.

• Innovent Biologics, Inc.

• QL Biopharmaceutical Co., Ltd.

• PegBio Co., Ltd.

• Tonghua Dongbao Pharmaceutical Co., Ltd.

• Sun Pharmaceutical Industries Ltd.

• Kallyope, Inc.

• Rani Therapeutics Holdings, Inc.

• Oramed Pharmaceuticals Inc.

Oral GLP-1 Therapeutics Market Report Scope: